Zura Bio Limited/$ZURA
1D1W1MYTD1Y5YMAX
Capital at risk
About Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
- Ticker
- $ZURA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 40
- Headquarters
- Henderson, United States
- Website
- zurabio.com
Zura Bio Limited Metrics
BasicAdvanced
$499M
-
-$1.09
-0.02
-
Price and volume
Market cap
$499M
Beta
-0.02
52-week high
$7.44
52-week low
$1.88
Average daily volume
1.4M
Financial strength
Current ratio
12.9
Quick ratio
12.571
Profitability
EBITDA (TTM)
-92.689
Effective tax rate (TTM)
0.09%
Management effectiveness
Return on assets (TTM)
-31.23%
Return on equity (TTM)
-51.01%
Valuation
Price to book
2.52
Price to tangible book (TTM)
2.52
Price to free cash flow (TTM)
-7.189
Free cash flow yield (TTM)
-13.91%
Free cash flow per share (TTM)
-0.725
Growth
Earnings per share change (TTM)
51.90%
3-year earnings per share growth (CAGR)
-49.37%
Bulls say / Bears say
Zura’s dual-antibody candidate tibulizumab has completed and exceeded enrollment in its Phase 2 TibuSHIELD trial in hidradenitis suppurativa and TibuSURE trial in systemic sclerosis, derisking near-term catalysts ahead of topline data readouts in Q4 2026 and H1 2027 (https://www.nasdaq.com/press-release/zura-bio-reports-second-quarter-2026-financial-results-and-recent-corporate-updates).
As of June 30, 2026, Zura held $205.1 million in cash and cash equivalents—enough to fund operations through at least the end of 2028—providing a solid runway to advance its clinical programs (https://www.nasdaq.com/press-release/zura-bio-reports-second-quarter-2026-financial-results-and-recent-corporate-updates).
Analyst coverage remains bullish: the average consensus rating is “strong buy” with a median 12-month price target of $15.00, implying roughly 150% upside from recent share prices (https://www.sahmcapital.com/news/content/zura-bios-fy-net-loss-widens-on-higher-rd-costs-2026-03-19).
R&D expenses rose to $14.7 million in Q1 2026 from $10.5 million in Q1 2025, intensifying cash burn during a pre-revenue stage (https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/zura-20260507.htm).
Net loss widened to $24.2 million, or $0.22 per share, in Q1 2026 versus $17.4 million, or $0.19 per share, in the year-ago quarter, reflecting mounting operating losses (https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/zura-20260507.htm).
Chief Financial Officer Eric Hyllengren separated from Zura Bio on April 20, 2026, potentially disrupting financial leadership amid critical Phase 2 developments (https://www.marketscreener.com/news/zura-bio-ltd-eric-hyllengren-separated-from-zura-bio-limited-as-cfo-on-april-20-2026-ce7f59dedc80f425/).
Data summarised monthly by Lightyear AI. Last updated on 27 Aug 2026.
Upcoming events
No upcoming events
Zura Bio Limited News
AllArticlesVideos
Funds containing Zura Bio Limited
Fund name | Fund size | $ZURA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.